Understanding Clinical Innovation

Here’s how clinical innovation translates to a new drug’s success:

Oncology Insights

Featured
Keytruda-paclitaxel-bevacizumab-Figure.jpg
Oncology
Keytruda Grabs its 42nd Approval in PD-L1+ PROC
Oncology
Read More →
Oncology
How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC
Oncology, R&D Insights
How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC
Oncology, R&D Insights
Read More →
Oncology, R&D Insights
Screenshot 2025-10-30 154345.png
Oncology, R&D Insights
What indications should we focus on?
Oncology, R&D Insights
Read More →
Oncology, R&D Insights
Enhertu regimen Figure (1).jpg
Oncology
Enhertu is poised to dominate first-line HER2+ breast cancer
Oncology
Read More →
Oncology
Yescarta.png
Oncology
CAR-T Outlook
Oncology
Read More →
Oncology
Enhertu-vs.-Kadcyla.jpg
Oncology
Enhertu shows high clinical innovation in second-line metastatic breast cancer
Oncology
Read More →
Oncology
Keytruda-and-Lenvima-Figure.jpg
Oncology
Weighing Efficacy vs. Tolerability: Lenvima + Keytruda in Advanced ccRCC
Oncology
Read More →
Oncology
amivantamab figure jpeg.jpg
Oncology
Rybrevant and Exkivity: two highly innovative new therapies to treat EGFR Exon 20 Insertion positive mNSCLC
Oncology
Read More →
Oncology
Capture3.JPG
Oncology
Prioritizing Indications: An Analytical Framework
Oncology
Read More →
Oncology
drivers.png
Oncology
Trodelvy: A New Option for Later Lines TNBC
Oncology
Read More →
Oncology
Onco Drivers.PNG
Oncology
Monjuvi: Newest Blockbuster in Relapsed/Refractory DLBCL
Oncology
Read More →
Oncology
Two indications.PNG
Oncology, R&D Insights
Comparing Opportunity Across Subpopulations: Rozlytrek as a Case Study
Oncology, R&D Insights
Read More →
Oncology, R&D Insights
Drivers.JPG
Oncology
Pfizer Combo Gains an Edge in BRAF+ Melanoma
Oncology
Read More →
Oncology
A Reliable Predictor of NICE Recommendation
Oncology
A Reliable Predictor of NICE Recommendation
Oncology
Read More →
Oncology
Brukinsa.png
Oncology
Brukinsa: Shooting behind the duck in R/R mantle cell lymphoma
Oncology
Read More →
Oncology
Drivers website.JPG
Oncology
Lynparza: Expanding into Prostate Cancer
Oncology
Read More →
Oncology
Bubble chart.JPG
Oncology, R&D Insights
Finding the Right Price for a Drug across Multiple Indications; Learnings from Keytruda
Oncology, R&D Insights
Read More →
Oncology, R&D Insights
drivers correct.JPG
Oncology
Enhertu: A New Leader in Later-Line Breast Cancer
Oncology
Read More →
Oncology
Zejula Updated.JPG
Oncology
PARP Inhibitors: Promise in New Maintenance Indications
Oncology
Read More →
Oncology
now onco.png
Oncology
Candidate Observations to Be Added to Equinox’s Oncology Normative Pricing Model
Oncology
Read More →
Oncology
Capture.JPG
Oncology
Tecentriq and Imfinzi Both Offer Modest Improvements in SCLC
Oncology
Read More →
Oncology
Drivers for Calquence.PNG
Oncology
Calquence: The price is right
Oncology
Read More →
Oncology
dfsdf.png
Oncology, R&D Insights
How to Price an Oncology Drug
Oncology, R&D Insights
Read More →
Oncology, R&D Insights
imbruvica 1.JPG
Oncology
Imbruvica: Closing the window of opportunity in CLL
Oncology
Read More →
Oncology
Oncology
Keytruda: Exceptional early results in a small colorectal cancer population
Oncology
Read More →
Oncology
Oncology
Blincyto: High price for an undifferentiated drug
Oncology
Read More →
Oncology
opdivo 1.png
Oncology
PD-1 Inhibitors: Strong starts in three indications
Oncology
Read More →
Oncology
avastin.png
Oncology
Avastin: One molecule in multiple cancers
Oncology
Read More →
Oncology
Oncology
Kyprolis: A rapid rise in a crowded market
Oncology
Read More →
Oncology